For HER2+ BC, Loi et al.[3] found TILs were associated with good DFS in patients who didn’t receive trastuzumab treatment in BIG 02–98, while TILs were found associated with trastuzumab benefit in FinHER study[41]. This evidence concerns the gene ERBB2 and breast cancer.